1. Scrip
  2. >>Business
  3. >>Financing

Clasp Launches With $150m To Develop Personalized T-Cell Engagers

Dual Agents Target Oncogenes And HLA Proteins

 
• By Mandy Jackson

Clasp Therapeutics, which emerged from labs at Johns Hopkins University and was incubated by a pair of venture capital investors, plans to achieve a clinical trial readout with its series A cash.

Start-up Funding Crowdfunding Investment Venture Capital Entrepreneurship Internet Business Technology Concept
Clasp will take at least one candidate into the clinic with its new funding • Source: Shutterstock

Clasp Therapeutics is developing next-generation T-cell engagers with the aim of developing off-the-shelf immuno-oncology therapeutics that have precise tumor targeting with limited on-target, off-tumor adverse events. And now with a $150m series A venture capital round announced on 20 March, the company plans to develop its first therapeutic candidates from preclinical all the way through initial clinical trial data.

Key Takeaways

  • Clasp Therapeutics launched with a $150m series A round to develop off-the-shelf T-cell engagers based on research conducted at Johns Hopkins University.

Cambridge, MA- and Rockville, MD-based Clasp emerged from the labs of cancer genetics specialist Bert Vogelstein and immuno-oncology researcher Drew...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Finance Watch: Lilly Toes The $1 Trillion Valuation Line

 
• By Mandy Jackson

Public Company Edition: Lilly’s obesity franchise makes it the highest-valued health care company in the US. Also, Genmab accesses $4.5bn to fund its $8bn Merus buy, Moderna locks in a $1.5bn credit facility and Ionis sells $700m worth of notes.

AimedBio IPO Raises Hopes Of Investor Appetite For Korean Biotech

 
• By Jung Won Shin

The success of AimedBio’s IPO may indicate investors are returning to the South Korean biopharma sector amid a series of large global out-licensing deals by domestic ventures and the strong performance of some recent biotech debutants on Kosdaq.

Finance Watch: Poxel Pulls Back From The Brink With Recovery Plan

 
• By Mandy Jackson

Restructuring Edition: Nxera will cut its workforce by 15% in Japan and the UK, among other changes. Also, nearing the end of its cash, Applied Therapeutics cuts 46% of its employees, Korro will cut staffing by 34% as it shifts focus and Metagenomi revealed a 25% workforce reduction.

Five Things To Know From Moderna’s Analyst Day

 
• By Joseph Haas

Still betting on its vaccines portfolio, Moderna is also hoping to deliver on its ambitions in oncology with a Phase III candidate partnered with Merck, while cutting pipeline programs and seeking manufacturing efficiencies.

More from Business

Sibeprenlimab’s US Accelerated Approval Drives IgAN Competition Forward

 
• By Lisa Takagi

Following US approval of its first-in-class drug for IgAN sibeprelimab, Otsuka is planning an sNDA for an autoinjector in 2026 and is in talks with regulatory authorities in Japan and Europe.

The Rise of China Biopharma – Five Themes In 2025

 
• By Andrew McConaghie

The growth of China’s biopharma sector has been perhaps the most significant sector trend this year – Scrip outlines five themes that have emerged during 2025 and in discussions at the recent Jefferies conference in London.

Lundbeck Concedes Avadel Bidding War, But Remains On The Hunt

 
• By Manas Mishra

Lundbeck does not plan to raise its offer for sleep specialist Avadel, clearing the way for Alkermes to win the two-way bidding war.